Analysts Offer Predictions for MiMedx Group FY2027 Earnings

by · The Markets Daily

MiMedx Group, Inc (NASDAQ:MDXG – Free Report) – Stock analysts at Northland Capmk issued their FY2027 earnings estimates for MiMedx Group in a research note issued to investors on Monday, November 3rd. Northland Capmk analyst C. Byrnes forecasts that the company will post earnings of $0.45 per share for the year. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share.

MDXG has been the subject of a number of other reports. Cantor Fitzgerald raised their price target on MiMedx Group from $11.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, July 31st. Weiss Ratings reissued a “hold (c)” rating on shares of MiMedx Group in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $12.00.

Check Out Our Latest Stock Report on MiMedx Group

MiMedx Group Price Performance

Shares of NASDAQ MDXG opened at $7.52 on Tuesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.39 and a quick ratio of 3.90. The business has a 50-day moving average of $7.00 and a 200-day moving average of $6.79. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of 27.85 and a beta of 1.73. MiMedx Group has a fifty-two week low of $5.79 and a fifty-two week high of $10.14.

MiMedx Group (NASDAQ:MDXG – Get Free Report) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.03) earnings per share (EPS) for the quarter. MiMedx Group had a net margin of 10.38% and a return on equity of 28.35%. The business had revenue of $67.69 million during the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Great Lakes Advisors LLC acquired a new position in shares of MiMedx Group during the 3rd quarter worth approximately $88,000. Hussman Strategic Advisors Inc. acquired a new stake in MiMedx Group during the 3rd quarter valued at $1,759,000. Wealth Enhancement Advisory Services LLC bought a new position in MiMedx Group during the third quarter worth $84,000. State of Alaska Department of Revenue acquired a new position in shares of MiMedx Group in the third quarter valued at $54,000. Finally, SG Americas Securities LLC increased its holdings in shares of MiMedx Group by 419.3% in the third quarter. SG Americas Securities LLC now owns 161,960 shares of the company’s stock valued at $1,130,000 after purchasing an additional 130,769 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors.

MiMedx Group Company Profile

(Get Free Report)

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.

Recommended Stories